Introduction {#s1}
============

D-Cycloserine (DCS) has a unique potential to target the glycine-binding site of N-methyl-D-aspartate (NMDA) receptors in humans. Alternative drugs applicable in human as well as in animal experiments are summarized in [Table 1](#T1){ref-type="table"}. DCS is a natural product of *Streptomyces orchidaceus* and *Streptomyces garyphalus*, which has been known in tuberculosis therapy since the late 1950s ([@CIT0047]). Years later, [@CIT0064] found its central active mechanism to be a selective partial NMDA agonist acting at the glycine-binding site of the NMDA receptor. It was postulated, and later proven on slice preparations, that DCS influences long-term potentiation (LTP), a neuronal mechanism thought to be relevant for learning ([@CIT0073]). Since then, neuropsychiatric studies have been carried out to evaluate the potential of DCS for neurological and psychiatric conditions such as Alzheimer's disease, schizophrenia, depression, and anxiety disorders. Even though DCS has already been approved by the U.S. Food and Drug Administration for human use (in tuberculosis therapy and some urinary tract infections), most research data on neuroplasticity is still preliminary, and some results are even heterogeneous. Here we review the literature investigating the therapeutic potential of DCS, especially in terms of its scientific and therapeutic potential, as well as its safety issues.

###### 

Agonists and Antagonists of the Glycine B Site of the NMDA-Receptor

  **Agonists**            **Antagonists**                              
  ----------------------- -------------------------------------------- --------------------------------------------------
  Full natural agonists   Glycine                                      Kynurenic acid and derivates (e.g. 5,7-diCl-KYN)
                          (R)-alanine                                  2-Carboxyindoles (e.g. L-689,560)
                          (R)-serine                                   2-Carboxytetrahydroquinolines
  Partial agonists        ACPC (1-Aminocyclopropane carboxylic acid)   4-Hydroxy-2-quinolones
                          ACBC (1-Aminocyclobutanecarboxylic acid)     Quinoxaline-2,3-diones
                          Cycloleucin                                  3-Hydroxy-1H-1-benzazepine-2,5-diones
                          D-Cycloserine                                Tricyclic glycineB site antagonists
                          HA-966 and derivates (e.g. L-687,414)        

For detailed information on different substances, see Danysz and Parsons (1998)

Neurophysiological Aspects {#s2}
==========================

The NMDA receptor plays a crucial role in cortical neuroplasticity through its mechanism called LTP. This has been proven to be relevant for various learning processes ([@CIT0073]) and thereby gives a strong rational for NMDA receptor influencing drugs (like DCS; see [Table 1](#T1){ref-type="table"}) to be used in illnesses that are based on deficits in neuroplasticity (eg, dementia) and/or therapies that rely on learning processes (eg, fear exposure therapy). The NMDA receptor consists of 2 subunits: NR1 and NR2 ([Figure 1](#F1){ref-type="fig"}). DCS acts at the glycine-binding site of the NMDA receptor, which is located at its NR1 subunit. In contrast to the natural binding substance, glycine (as well as D-alanine and D-serine), DCS acts as a partial agonist ([@CIT0074]), meaning that in vivo, it acts like an agonist at low doses but has antagonistic features with high doses. This seems to be due to its different receptor subtype selectivity and intrinsic action, which depends on various NR2 subunits (NR2A, NR2B, NR2C), the location of glutamate binding ([@CIT0013]). Presumably, the effects seen in vivo at low doses of DCS reflect its agonistic action at the NR1/NR2C receptors, for which it has a high affinity, while at high doses the effects might be due to antagonistic inhibition of NR1/NR2A and NR1/NR2B receptors, for which DCS has a lower affinity ([@CIT0010]).

![Schematic structure of the NMDA receptor.\
The NMDA receptor consists of 2 subunits (NR1 and NR2A, NR2B or NR2C). The NR2 subunits hold the glutamate binding site (GluBS), where the main agonist glutamate (Glu) binds. The NR1 subunit holds the glycine binding site (GlyBS), where the natural co-agonist glycine (Gly) or the partial agonist D-Cycloserine (DCS) bind.\
For further agonists and antagonists of the GlyBS see [Table 1](#T1){ref-type="table"}. For further details on the structure of the NMDA receptor see [@CIT0013].](ijnppy_pyv102_f0001){#F1}

When targeting NMDA receptors that consist of NR2C subunits, DCS produces a 200% depolarization (compared with glycine) that is not pH-sensitive and seems not to depend on concentrations of glycine ([@CIT0059]). NR2C units are mainly expressed in cerebellar structures, but are also found in the striatum, hippocampus, olfactory bulb, retrosplenial cortex, thalamus, pontine, and vestibular nuclei ([@CIT0035]). NR2C knockout mice show deficits in tests of fear acquisition and working memory, implying that NMDA receptors consisting of NR2C subunits play a substantial role in fear learning processes ([@CIT0030]). In healthy animals, DCS leads to a better extinction of conditioned fears ([@CIT0072]; [@CIT0038]), enhances consolidation and retrieval of memories ([@CIT0054]), and improves visual recognition memory ([@CIT0039]). Interestingly, facilitation of the fear extinction process works only once, whereas the retrieval of a previous extinction memory (reextinction) seems not to be influenced by DCS ([@CIT0037]). With repeated applications, a reduction in efficacy has been shown in chronic administration of DCS in animals ([@CIT0054]). A mechanism of endocytosis of the receptor has been hypothesized ([@CIT0045]), according to which a single dose of DCS, but not repeated doses, may improve cognition in humans ([@CIT0021]). Furthermore, a meta-analysis on exposure therapy showed that DCS is more efficacious when administered only a limited number of times ([@CIT0046]).

The mechanism of action of DCS might change or even reverse under conditions with great stress and might be due to different surrounding neurotransmitter concentrations ([@CIT0033]; [@CIT0074]; [@CIT0059]; [@CIT0012]). In line with this, DCS was shown to partially reverse the deficits of fear extinction learning due to sleep deprivation in ("stressed") rats ([@CIT0060]). This, however, could not be reproduced in humans in a large multi-center study on the efficacy of cognitive behavioral therapy in correlation with sleep quality and DCS administration ([@CIT0077]). This study is probably not directly comparable, since subjects self-reporting a feeling of "not being rested" might not reflect sleep deprivation in rats in terms of stress. Nevertheless, the possible impact of stress on the efficacy of DCS should be taken into account when conducting trials with this substance in neuropsychiatric diseases, especially those that go along with sleep disturbances (eg, depression) or fear (eg, schizophrenia, anxiety disorders).

Altogether, DCS seems to have an impact on cognitive functions, mainly those associated with NMDA receptor-dependent mechanisms like LTP in learning processes. Part of this effect seems to be a stabilization of NMDA receptors, with a consequent facilitation of cortical neuroplasticity, as has been proven neurophysiologically via transcranial direct current stimulation ([@CIT0044]; [@CIT0036]; [@CIT0007]). Clinically, neurorehabilitation might benefit from DCS, since it improved functional recovery after cerebral damage in a mouse model ([@CIT0001]).

Safety Aspects {#s3}
==============

DCS has been used for over one-half a century in tuberculosis therapy, the doses used for this indication being clearly up to about 20 times higher than for modulation of neuroplasticity. The pharmacological properties and side effects are well known and have been described elsewhere ([@CIT0022]; [@CIT0050]). To summarize, the maximum concentration (20--35 µg/mL) in blood is reached 2 hours after oral application of 250 to 500mg DCS. Half-life time varies from 8 to 12 hours depending on renal function. About 54% to 79% of oral intake reaches the cerebrospinal fluid. The typical application interval in antituberculosis therapy is 250 to 500mg twice daily ([@CIT0050]). Side effects, mainly associated with high dosages, include hyperexcitability, dizziness, depression, anxiety, confusion, memory loss, and lethargy, as well as very rare seizures (especially with blood levels exceeding 35 µg/mL). Gastrointestinal trouble, rash, allergy, fever, and cardiovascular problems (including cardiac arrhythmia) are also described on rare occasions ([@CIT0022]; [@CIT0050]).

The possibility of seizures has been investigated further. So far, animal studies report DCS to have more of an anticonvulsive effect than otherwise, especially in low-dose applications ([@CIT0076]). As no changes were seen in the cerebral levels of neuronal amino acids, such changes are unlikely to be the cause of the rarely described convulsive side effects of DCS in humans ([@CIT0003]).

We conducted a Medline search using the search item "D-cycloserine" with the filter of "Clinical trial" and "Human." Studies up until December 2014 were included. The reference lists of the identified studies were examined for further studies. All studies were examined by the 2 authors of this review for applicability. In vitro trials, trials in tuberculosis therapy, as well as recalculations of former data were excluded by definition. Results can be found in [supplementary Material](http://ijnp.oxfordjournals.org/lookup/suppl/doi:10.1093/ijnp/pyv102/-/DC1). In 91 studies, more than 2100 patients were treated with DCS (mainly single doses or once weekly with a maximum dosage of 500mg/d) (for details on dosing, see [supplementary Material](http://ijnp.oxfordjournals.org/lookup/suppl/doi:10.1093/ijnp/pyv102/-/DC1)). Frequent complaints of the DCS patients included psychopathological stimulation (eg, anxiety, euphoria, agitation, feeling "stimulated"), dizziness/drowsiness, fatigue, headache, and gastro-intestinal disturbance, similar to placebo controls (n\>1500). Drop-out rates were also similar between verum and placebo. The highest drop-out rate was reported by [@CIT0020] while conducting a 6-month trial in schizophrenia patients with 50mg/d DCS coadministered with conventional antipsychotics. More detailed analysis of the subjects in this study did not show a difference between placebo and verum, reinforcing the theory that the high drop-out rate is not drug related but illness-associated, since long-term studies with schizophrenic patients often have high drop-out rates ([@CIT0065]).

When administering DCS in studies with patients, interactions with other drugs should be taken into account. For instance, antidepressants such as imipramine or citalopram can offset the facilitating effect on extinction of DCS in animals ([@CIT0051]; [@CIT0075]). Neuroleptics such as olanzapine and clozapine seem to impair the effects of DCS as well, especially in schizophrenic patients ([@CIT0018]; [@CIT0017]; [@CIT0071]).

Therapeutic Implications {#s4}
========================

DCS is a typical example of translational research from neurobiochemical considerations to animal experiments and application in various neuropsychiatric diseases. First, the central acting mechanism of DCS was found ([@CIT0064]). DCS acts at the glycine-binding side of the NMDA receptor and thereby modulates its activity. It has been proven that NMDA receptors play a crucial role in neuroplasticity of the human brain through a mechanism called LTP ([@CIT0073]). This led to the rationale that DCS might modulate neuroplasticity, which has been proven in humans by neurophysiological studies with transcranial direct current stimulation ([@CIT0044]; [@CIT0036]; [@CIT0007]). Neuroplasticity itself plays an important role in higher cognitive functions like learning and memory. Therefore, DCS might modulate these processes, which gave the rational of studying the effects of DCS on diseases associated with memory/learning deficits (eg, dementia, autism) on therapies that rely on learning processes (eg, exposure therapy in anxiety disorders or cue exposure therapy in addiction). In the following, various clinical applications of DCS in neuropsychiatric diseases will be outlined.

Psychiatric Diseases {#s5}
--------------------

The rationale of DCS in psychiatric diseases like schizophrenia and depression is based on the glutamate hypothesis, although the exact mechanisms of the pathology are unknown. In schizophrenia, the fact that glutaminergic antagonists model symptoms of the disease and that genes of the glutaminergic system are associated with a higher risk of schizophrenia strengthens this hypothesis ([@CIT0024]). Since the NMDA receptor plays an important role in the glutaminergic system, its partial agonist DCS was speculated to influence symptoms of the disease. A pioneering group with Donald C. Goff in Harvard first investigated the therapeutic value of DCS in schizophrenia. Early studies showed a dose-dependent improvement in negative symptoms (affective flattening, alogia, avolition, anhedonia and attentional impairment) ([@CIT0002]) in schizophrenic patients with best results at a dose of 50mg/d ([@CIT0016], [@CIT0019]; [@CIT0025]; [@CIT0026]). However, DCS in combination with conventional neuroleptics (clozapine, olanzapine) caused negative symptoms to worsen ([@CIT0018], [@CIT0017]; [@CIT0071]), though further studies later showed no or only marginal effects of DCS on negative symptoms ([@CIT0014]; [@CIT0020]; [@CIT0005]). There might be different reasons for these seemingly contradictory results. Some could be due to the above-described, only partially agonistic, nature of DCS, which has been underlined just recently in a quantitative systems pharmacology-based computer modeling of complex humanized brain circuits ([@CIT0062]). Another reason might be the possibility of an endocytosis of the receptors, especially considering that weekly rather than daily dosages did show positive effects of DCS on negative symptoms in schizophrenia ([@CIT0021]). Overall, 2 meta-analyses, balancing the quality discrepancies of the aforementioned studies, find other glutaminergic drugs to be more efficient in schizophrenia than DCS, probably due to its narrow therapeutic window caused by its partial agonistic mechanism ([@CIT0068]; [@CIT0066]).

In contrast to schizophrenia, an overactive glutamate system is speculated in depression. Therefore, studies in treatment-resistant major depression hypothesize a beneficial antidepressant effect of DCS due to its antagonistic mechanism in higher doses. A first study with 250mg/d DCS as add-on therapy to various stable psychotropic medications failed to show positive results ([@CIT0027]). A further study with a dose of up to 1000mg/d, however, then showed an improvement in depression symptoms ([@CIT0028]), indicating an antagonistic mechanism in doses starting at 500mg/d in humans.

The hypothesis of autism being a hypoglutamatergic disorder was first introduced by [@CIT0006] and supported by genetic mouse models of the disease (for references, see [@CIT0069]). A preliminary study by [@CIT0052] showed positive effects of DCS by reducing social withdrawal and increasing social responsiveness. More recently, positive effects of DCS on stereotypies ([@CIT0069]) and social deficits ([@CIT0070]) were also seen in older adolescents and young adults with autism spectrum disorder. All data so far have to be interpreted with caution, because of several weaknesses of the studies (small sample size, no placebo control, lack of clinical blinding in the study of [@CIT0052]). Therefore, further studies need to replicate and expand these results.

High expectations have also been raised with regard to a combination of DCS with cognitive behavioral therapy (CBT). The rationale that NMDA receptors are highly involved in learning processes like conditioning and deconditioning (as outlined above) led to several studies in the fields of anxiety and panic disorders as well as dependency. Further supported by animal studies that showed a more rapid extinction of fear with DCS ([@CIT0072]; [@CIT0038]), the hope was that DCS would accelerate the effects of behavioral therapy (especially exposure therapy) and thereby improve therapy compliance and outcome. A huge meta-analysis ([@CIT0046]) of data from human and animal studies showed a significant, though moderate, positive effect of DCS on exposure therapy/fear extinction. In anxiety-disordered humans, this was mainly due to a better speed/efficacy of the therapy rather than its better overall outcome, because it produced a faster (and therefore more economic) result ([@CIT0046]). This is in line with the results of a recent multi-site study on CBT and DCS in social anxiety disorder ([@CIT0031]). Further promising results have been found, especially for the combination of DCS and CBT, in patients with anorexia nervosa (food exposure therapy) ([@CIT0063]) and obsessive-compulsive and panic disorder as well as with phobias ([@CIT0011]). The time-point of drug application (before/after CBT), the frequency of drug administration, and the correct dosages are still the focus of research, mainly because the above-mentioned meta-analysis showed a correlation of these factors with efficacy in augmenting CBT. This seems to be mainly based on the animal data, since a second meta-analysis, this time including only data with humans, could find no such correlations (though it still also underlined the positive effect of DCS in combination with CBT) ([@CIT0004]). From animal models we know that administration of DCS (maximum 4 hours) after a fear extinction experiment shows better results than an application before the experiment ([@CIT0038]). It has also been demonstrated that the efficacy of DCS wears off if administered frequently, unless the time interval between applications is long enough ([@CIT0049]). Perhaps even just one single application of DCS might be sufficient, as long as it is used to augment de novo CBT (as opposed to repeated CBT) ([@CIT0023]). For more information on DCS as an augmentation strategy in CBT for anxiety disorders, see 2 detailed recent reviews ([@CIT0032]; [@CIT0061]).

In addiction, cue exposure therapy (CET) aims to reduce conditioned reactions to substance cues. This process is believed to be a form of extinction learning rather than a form of "unlearning." Since NMDA receptors are generally accepted to play a crucial role in extinction learning (eg, fear extinction), it was hypothysed that DCS might enhance CET. Some preliminary data on addiction therapy have shown promising results from using DCS in combination with CET in nicotine ([@CIT0057]). In cocaine dependency, however, increased craving during the sessions has been reported, maybe due to the glutamatergic effect of DCS ([@CIT0053]). Therefore, the correct timing of drug intake might be crucial to avoid stimulating the patient during cue exposure while also facilitating extinction learning afterwards. Due to weaknesses of the aforementioned studies and the limited number of participants so far (for a detailed review, see [@CIT0042]), more studies involving DCS, CET, and addiction are needed, though it should be mentioned that CET itself seems to be still under debate ([@CIT0009]).

Neurological Diseases {#s6}
---------------------

In Alzheimer's disease, next to the well-established cholinergic deficit, a glutaminergic dysregulation has been found and an NMDA receptor dysfunction has been proven (for details, see [@CIT0041]). Since positive modulation of NMDA receptors may lead to enhanced memory and learning (through LTP), DCS has been suggested to improve cognitive capacities in Alzheimer's disease. First studies were disappointing and showed no ([@CIT0055]; [@CIT0015]) or only marginal ([@CIT0058]) effects on cognition. A meta-analysis of 2 large, multi-center parallel group studies of 6-months duration (partially unpublished data) was unable to show that DCS had a positive effect on cognitive outcomes ([@CIT0034]). Due to its relatively high statistical power, the authors concluded that DCS has no place in the treatment of patients with Alzheimer's disease. Study designs have to be reconsidered, however. The above-discussed possibility of a wearing-off effect, perhaps due to a downward regulation of the receptor, might be a reason for the weak effect of DCS on cognition in these studies, since DCS had been administered on a daily basis (sometimes twice daily). Only [@CIT0067], treating patients with Alzheimer's disease with DCS once weekly, were able to observe an improvement in cognition.

There has been one study on diseases with spinocerebellar degeneration that investigated the effect of DCS on ataxia symptoms, motivated by the consideration that impaired (mainly cerebellar) glutamatergic projections might be a part of the underlying pathophysiology ([@CIT0048]). The data, though preliminary, are somewhat promising, since they show improvements on ataxia scales, thereby replicating former animal data ([@CIT0056]), but the results still need to be replicated by independent groups with a larger number of subjects.

NMDA receptors are also involved in motor learning through LTP, which has been proven in animal experiments ([@CIT0029]), and DCS facilitates motor learning in neurophysiological trials ([@CIT0044]). Since motor learning plays a crucial role in neurorehabilitation (eg, after stroke), the rationale of DCS improving outcomes of neurorehabilitative therapies has been drawn. Unfortunately, recent studies failed to show a positive effect of an add-on therapy with DCS to motor/movement therapy ([@CIT0008]; [@CIT0043]).

Conclusions and Future Prospects {#s7}
================================

Studies with DCS represent an exceptional example of translational scientific work, applying animal data toward the design of human studies. This is not least also due to the fact that DCS had already been approved for human use in other applications. As a well-known drug in tuberculosis therapy, it has been found to be safe, especially in lower dosages, as has again been shown in our review in a new application. The most promising results have been found in combining DCS with CBT in various neuropsychiatric diseases. In accordance, a search for ongoing, registered trials (U.S. National Library of Medicine) reveals mainly studies in this field, examining the effect of DCS on CBT in anxiety disorders, addiction, schizophrenia, and depression. A few exploratory trials also study traumatic brain injury, pain, and dyspnea perception or tinnitus. Nevertheless, newer research is increasingly encountering the limitations of the drug, mainly due to its dose-dependent partially agonistic/antagonistic mechanism (the optimal dosage seems to be crucial, but perhaps inter-individually different), its loss of efficacy on regular application (hypothesized downward-regulation of the receptors), as well as its low specificity with regard to the different subunits of NR2 with probably different pharmacological profiles. Therefore, the step "back to bench" with the development of new (more specific) substances might be worthwhile, while keeping our knowledge of DCS in mind ([@CIT0040]).
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